Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)
It is very uncertain whether extracorporeal shock wave treatment (ESWT) changes discontinuation from treatment compared with sham (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes discontinuation from treatment compared with placebo (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
It is very uncertain whether penile traction therapy changes discontinuation from treatment compared with no treatment (short‐term) (very low certainty).
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · psoriasis
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Docetaxel showed no clear difference in treatment discontinuation due to toxicity compared with non‐docetaxel‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Capecitabine showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether oxaliplatin changes treatment discontinuation due to toxicity compared with the same regimen including cisplatin (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review
Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).
1 finding from 1 review
All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Intervention not reported
Discontinuation of treatment due to side effects ( · people with or at risk of cardiovascular disease
The intervention probably leads to higher discontinuation of treatment due to side effects ( (moderate certainty).
1 finding from 1 review